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ABSTRACT
Cancer cells become dependent on aerobic glycolysis to sustain rapid proliferation and escape apoptosis.
How this metabolic change, also known as the Warburg effect, is linked to apoptosis remains largely
unknown. Our new data place c-Jun N-terminal kinase in the center of a hub regulating apoptosis and
cancer metabolism. KEYWORDS
Aerobic glycolysis; cancer;
JNK; PARP14; PKM2
The c-Jun N-terminal kinases (JNKs) are members of a larger
group of serine/threonine (Ser/Thr) protein kinases known as
mitogen-activated protein kinases (MAPKs).1 Like many other
members of the MAPK family that regulate a large variety of
cellular functions, the role of JNKs in cancer is complex.2 For
certain type of cancers, activation of JNK signaling has been
described as a key tumor promoter factor; in other cancer set-
tings JNK activation is needed for promotion of apoptosis of
malignant cells, especially in response to chemotherapeutic
drugs inhibiting speciﬁc oncogenic signals. This dichotomy is
in part explained by the fact that 2 ubiquitously expressed JNK
isoforms (JNK1 and JNK2) function differently depending on
the cellular context. This complexity could be also due to the
increased number of downstream substrates that are activated
by JNKs.1,2
Originally named JNKs for their ability to phosphorylate
and activate the transcription factor c-Jun, the number of JNK
substrates has considerably increased since their discovery and
characterization.1 Many JNK substrates are also transcription
factors themselves, therefore the JNK-mediated effects are fur-
ther boosted by these cascades of activation.1 Recent work from
our group has identiﬁed the pyruvate kinase M2 isoform
(PKM2) as a novel and direct substrate of JNK1, adding
another piece to the complexity of the JNK cascade.3 We have
shown that the basal activity of JNK1 is masked by enhanced
expression of the antiapoptotic protein poly(ADP-ribose) poly-
merase family member 14 (PARP14) in a variety of human can-
cer cells. Remarkably, PARP14 expression is also associated
with poor patient prognosis.3,4 Mechanistically, PARP14 pro-
motes the survival of cancer cells by binding and inhibiting
JNK1.3,4 This inhibition promotes the Warburg effect and gly-
colytic gene expression by enhancing the activity of pyruvate
kinase isozyme type M2 (PKM2). PARP14, therefore, restricts
PKM2 activity through inactivation of JNK1 signaling (Fig. 1).3
PKM2 is a tumor-speciﬁc isoform of the glycolytic enzyme
pyruvate kinase (PK), which catalyzes the synthesis of pyruvate
and ATP using phosphoenolpyruvate (PEP) and ADP as sub-
strates.5 Recent research in cellular metabolism has recognized
PKM2 as a critical mediator of the Warburg effect.5-9 Cancer
cells, like all highly proliferating cells, facilitate the uptake of
glucose and the incorporation of glycolytic metabolites into
amino acids, nucleic acids, and lipids (Fig. 1).6 Moreover, while
adapting to these new metabolic needs, the Warburg effect pro-
duces increased levels of antioxidant proteins to detoxify reac-
tive oxygen species (ROS), which would result in apoptosis
resistance in tumor tissues and therefore contributes to uncon-
trolled growth.5,6 Reduced PKM2 activity allows the accumula-
tion of glucose-6-phosphate (G6P), shifting the glucose ﬂux
through the pentose phosphate pathway (PPP) to generate
reduced nicotinamide adenine dinucleotide phosphate
(NADPH) and consequently antioxidant reduced glutathione
(GSH). On the contrary, increased PKM2 activity shifts G6P
toward pyruvate formation with consequential loss of antioxi-
dant capacities. These losses eventually lead to accumulation of
ROS and apoptosis of cancer cells.5 Therefore, regulation of
PKM2 activity is essential in the life and death decision of can-
cer cells (Fig. 1). The key question is: What makes PKM2
switch from a high- to low-activity state?
Coimmunoprecipitation analyses revealed that PKM2
formed a stable complex with JNK1 in HEK293T cells co-
expressing JNK1 and PKM2.3 Notably, this association was
speciﬁc for JNK1 as no interaction was detected between
JNK2 and PKM2. Endogenous interaction of PKM2 and
JNK1 was also detected in different cancer cell types. To
establish whether this interaction was direct or mediated by
other intermediary proteins, we also demonstrated that bac-
terial puriﬁed PKM2 tightly bound to JNK1. Unlike the
well-known interaction between PKM2 and death-associated
protein kinase (DAPK),10 the JNK1/PKM2 interaction
requires the presence of “phospho-active” JNK1 to enhance
the activity of PKM2, suggesting that the interaction alone
is not sufﬁcient to regulate PKM2 activity but phosphoryla-
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tion may be required. In vitro kinase assays and mass spec-
trometry analyses demonstrated the direct phosphorylation
of PKM2 Thr365 by JNK1. Consequently, the activity of
PKM2 is intensiﬁed by JNK1 phosphorylation in a dose-
dependent manner.3 In cancer cells, although basal JNK1
activity is not sufﬁcient to promote PKM2 phosphorylation
and drive apoptosis, enhanced JNK1 phosphorylation
induced by the absence (or inhibition) of PARP14 greatly
enhanced PKM2 activity and inhibited the Warburg effect
with consequential cell death. Therefore, we demonstrated
that the PARP14-JNK1-PKM2 regulatory axis is an impor-
tant determinant for the Warburg effect in tumor cells and
provides a mechanistic link between apoptosis and
metabolism.3
The notion that PKM2 is subject to post-translational
modiﬁcation to change its catalytic activity or cellular func-
tion is not novel.7 Direct phosphorylation of PKM2 Tyr105
by ﬁbroblast growth factor receptor type 1 (FGFR1) inhibits
its catalytic activity, providing a metabolic advantage to
tumor cells.8 Phosphorylation of Tyr105 uncouples the
binding of fructose-1,6-biphosphate preventing the forma-
tion of active tetrameric PKM2. Additional phosphorylation
sites have been also described. For instance, ERK2-depen-
dent phosphorylation of PKM2 Ser37 helps to recruit pep-
tidyl-prolyl cis-trans isomerase NIMA-interacting 1 (PIN1)
for cis-trans isomerization of PKM2, which serves to trans-
locate PKM2 to the nucleus.9 Although phosphorylation of
PKM2 Ser37 has no effect on the activity of PKM2 itself,
nuclear PKM2 acts as a co-activator of b-catenin to induce
c-MYC and glycolytic gene expression, therefore stimulating
tumor growth through indirect mechanisms.9 In addition to
PKM2 phosphorylation, amino acid acetylation, glycosyla-
tion, and oxidation, as well as protein-protein interactions
with regulatory components have been also largely charac-
terized, further validating the importance of PKM2 in
tumor metabolism.7
Accumulating evidence suggests that cancer cells rely on a
variety of metabolic reprograming activities.6 One of these phe-
nomena is the Warburg effect, in which cancer cells take up
more glucose than normal cells and use it to generate reducing
equivalents (such as NADPH, GSH) and macromolecules
(such as nucleotides, proteins, and lipids) required to suppress
apoptosis and generate biomass, respectively.6 Therefore,
understanding the molecular mechanism regulating this meta-
bolic shift may provide ways to improve cancer therapeutics.
Our new study offers a novel pathway whereby the PARP14-
JNK1-PKM2 axis might be used as target to induce cell death
through the inhibition of the Warburg effect in multiple cancer
types without causing side effects in normal cells that use alter-
native processes of energy.3
Figure 1. Major signaling pathways in glycolytic cancers. Schematic illustration of the intracellular pathways activated in glycolytic cancer cells. Green line: oncogenic
stimuli promote the overexpression of tumor initiating molecules (i.e., PARP14). Red line: accumulation of cellular stress activates the JNK cascade that consists of mito-
gen-activating protein kinase kinase kinase (MAP3K), which in turn phosphorylates and activates mitogen-activated protein kinase kinase 7 (MKK7), a direct activator of
JNK. Blue line: cancer cells are fuelled by glucose, which is transported into the cells via glucose transporters (GLUT). Much of the intracellular glucose is converted into
lactate by glycolytic enzymes, the most important ones being hexokinase (HK), phosphofructokinase (PFK), and pyruvate kinase isozyme type M2 (PKM2). The high levels
of PARP14 observed in cancer cells halt JNK1-mediated phosphorylation of downstream substrates (i.e., PKM2), thus maintaining low PKM2 activity. Consequently, there
is an accumulation of upstream glycolytic intermediates that favors the synthesis of cellular building blocks (i.e., amino acid, lipids, nucleotides) that are used to generate
daughter cells. During the branching of these synthetic pathways, antioxidants are also produced to counteract the cell-damaging products (i.e., reactive oxygen species
[ROS]). In the event of failure to halt JNK1-mediated phosphorylation and activation of PKM2, cancer cells die by apoptosis as a result of enhanced accumulation of intra-
cellular ROS.
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